Statins stand among the most vital medications prescribed globally for the prevention of cardiovascular disease. By effectively lowering cholesterol levels in the bloodstream, these drugs have helped save millions of lives over the decades, substantially reducing the likelihood of debilitating heart attacks and strokes for a vast population of patients. However, these profound medical benefits can occasionally come paired with unwanted and disruptive side effects. While a significant number of patients report developing persistent muscle pain, weakness, or fatigue, a much smaller proportion experiences a severe form of muscle breakdown known as rhabdomyolysis, which has the potential to cause acute kidney failure and other life-threatening complications.
Now, a team of scientists at the University of British Columbia (UBC), working alongside collaborative researchers at the University of Wisconsin-Madison, has successfully identified the precise molecular mechanism that helps explain these physiological complications. Their landmark findings, which have been officially published in the scientific journal Nature Communications, could pave the way for the future development of safer statin medications that maintain their crucial cholesterol-lowering properties while effectively minimizing or eliminating unwanted muscle damage.
How Statins Trigger a Harmful Calcium Leak
To thoroughly investigate what happens inside human muscle cells at a microscopic level, the research team utilized cryo-electron microscopy. This advanced, high-resolution imaging method allows modern scientists to examine complex protein structures in remarkable detail, providing clear visual data that was previously impossible to capture. The team’s exhaustive investigation centered squarely on the ryanodine receptor, designated as RyR1, which is a critical specialized protein responsible for regulating the delicate movement and storage of calcium within muscle cells.
Under normal, healthy physiological conditions, this specific protein functions as a strictly controlled cellular gateway, releasing calibrated bursts of calcium when muscles actively need to contract during physical movement. However, the researchers discovered that statin molecules can directly interfere with this intricate process by locking the channel open. As a consequence of this interference, calcium escapes continuously into cellular areas where it should otherwise be carefully regulated, ultimately creating an internal cellular environment that can injure and degrade muscle tissue over time.
"We were able to see, almost atom by atom, how statins latch onto this channel," said lead author Dr. Steven Molinarolo, a postdoctoral researcher working within UBC’s department of biochemistry and molecular biology. "That leak of calcium explains why some patients experience muscle pain or, in extreme cases, life-threatening complications."
Three Statin Molecules Reveal the Mechanism Behind Muscle Damage
During their investigation, the research team concentrated heavily on atorvastatin, which is one of the most commonly prescribed medications used globally for managing and lowering high cholesterol levels. Although this particular pharmaceutical drug served as the primary focus of the laboratory experiments, the team’s broader results strongly suggest that similar molecular interactions could potentially occur with other medications belonging to the wider statin family.
One of the most striking and unexpected discoveries during the study was the unusual way in which statin molecules physically attach themselves to the cellular calcium channel. Rather than acting individually or in isolation, the researchers observed that three distinct molecules occupy a specific, localized pocket within the protein structure. The first molecule binds to the channel while it is in a closed state, which paradoxically makes the protein more likely to open up. Subsequently, two additional molecules enter the same binding pocket and actively hold the channel open, allowing the pathological flow of calcium to continue leaking unchecked.
"This is the first time we’ve had a clear picture of how statins activate this channel," said Dr. Filip Van Petegem, the senior author of the study and a professor at UBC’s Life Sciences Institute. "It’s a big step forward because it gives us a roadmap for designing statins that don’t interact with muscle tissue."
This highly detailed structural understanding could eventually provide pharmaceutical drug developers with a viable way to address the longstanding clinical problem directly at its source. By chemically modifying the specific functional features of statin molecules that inadvertently interfere with human muscle proteins, scientists may soon be able to engineer new formulations that reduce these unwanted side effects without compromising the drugs’ proven ability to control cholesterol and protect the cardiovascular system.
A Potential Path Toward Safer Cholesterol Drugs
Globally, more than 200 million people rely on statins as a cornerstone of their daily healthcare routine. Although severe, dangerous muscle injury occurs in only a very small percentage of patients taking these medications, less serious problems such as muscle soreness, physical weakness, and profound fatigue are considerably more widespread among the general patient population. For many individuals, these uncomfortable symptoms can be disruptive enough that they choose to discontinue their medication entirely, thereby unwittingly losing crucial medical protection against cardiovascular disease and increasing their long-term risk of adverse cardiac events.
This groundbreaking molecular discovery could eventually help researchers create pharmacological treatments that are significantly easier for patients to tolerate. By improving tolerability, a larger number of patients could continue taking their prescribed medications consistently, maintaining essential defenses against heart attacks and strokes without enduring daily discomfort.
Achieving this unprecedented level of structural understanding required exceptionally detailed imaging technology and collaborative expertise. Working closely with the high-resolution macromolecular cryo-electron microscopy facility housed within UBC’s faculty of medicine, the research team was able to observe precisely how statin molecules physically interact with the vital muscle protein at an atomic level. These critical structural insights successfully connect a longstanding drug safety concern to a clearly defined molecular process, providing an invaluable foundation for future medication development and refinement.
"Statins have been a cornerstone of cardiovascular care for decades," Dr. Van Petegem noted, reflecting on the broader implications of the work. "Our goal is to make them even safer, so patients can benefit without fear of serious side effects."
Although additional scientific research, clinical testing, and extensive drug development will naturally be required before these laboratory findings successfully translate into tangible new pharmaceutical treatments available on the market, they undoubtedly offer a highly promising scientific direction. For the millions of people worldwide who depend on statins every single day to protect their hearts, future generations of medications designed with fewer muscle-related complications could make preventative treatment much more comfortable and meaningfully improve everyday quality of life.
